Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism

Minsub Shim and Thomas E. Eling
Minsub Shim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Eling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-0470 Published April 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    VES induces cell death and growth arrest in PC-3 cells. A, PC-3 cells were plated on a six-well plate and each group (three wells) was treated with various concentrations of VES for 48 h. After VES treatment, cells were trypsinized and combined with floating cells. The number of trypan blue–stained cells was counted. B, PC-3 cells were plated on a six-well plate and each group (three wells) was treated with various concentrations of VES for 48 h. After treatment, attached cells were harvested by trypsinization and counted under the microsccope.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    VES induces NAG-1 protein/mRNA expression in a concentration- and time-dependent manner. A, PC-3 cells were treated with the indicated concentrations of VES for 48 h and total lysates were subjected to Western blot analysis for NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. The membrane was stripped and reprobed for β-actin to confirm equal loading. B, PC-3 cells were treated with 20 μmol/L VES for the indicated amount of time and total cell lysates were subjected to Western blot analysis for NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. The membrane was stripped and reprobed for β-actin to confirm equal loading. C, PC-3 cells were treated with the indicated concentrations of VES for 48 h and mRNA was subjected to Northern blot analysis for NAG-1. The membrane was stripped and reprobed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to confirm equal loading of RNA. D, PC-3 cells were treated with 20 μmol/L VES for indicated amount of time and mRNA was subjected to Northern blot analysis for NAG-1. The membrane was stripped and reprobed for glyceraldehyde-3-phosphate dehydrogenase to confirm equal loading of RNA. E, PC-3 cells were transfected with NAG-1 promoter reporter plasmid (-966/70) and phRL-null plasmid. Twenty-four hours after transfection, cells were treated with 20 μmol/L VES for 48 h. NAG-1 promoter reporter activity was normalized to Renilla luciferase activity.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    VES induces NAG-1 protein/mRNA expression in a p38 kinase-dependent mechanism. A, PC-3 cells were treated with 20 μmol/L VES for the indicated amount of time, and total cell lysates were subjected to Western blot analysis for NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. Membranes was stripped and reprobed with indicated antibody. B, PC-3 cells were pretreated with 2.5 μmol/L Go6983, 20 μmol/L PD980509, 20 μmol/L Ly294002, 20 μmol/L SP600125, or 20 μmol/L SB203580 for 50 min and treated with 20 μmol/L VES for 48 h. Total cell lysates were subjected to Western blot analysis for NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. C, PC-3 cells were pretreated with 20 μmol/L SB203580 or SB202190 for 50 min and treated with 20 μmol/L VES for 48 h. Total cell lysates were subjected to Western blot analysis for NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. CTL, vehicle treated. D, PC-3 cells were pretreated with 20 μmol/L SB203580 for 50 min and treated with 20 μmol/L VES for 48 h. Total RNA was purified and 5 μg total RNA was reverse transcribed. The level of NAG-1 cDNA was analyzed with real-time PCR analysis. CTL, vehicle treated; SB203580, treated with SB203580; SB203580/VES, pretreated with SB203580 before VES treatment; VES, VES treated.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    VES induces p38 kinase activation and nuclear translocation. A, PC-3 cells were pretreated with 20 μmol/L SB203580 for 50 min and treated with 20 μmol/L VES for 48 h. Total cell lysates were subjected to Western blot analysis for phospho-Hsp27. Membrane was stripped and reprobed for total Hsp27. CTL, vehicle treated; SB203580, treated with SB203580; SB203580/VES, pretreated with SB203580 before VES treatment; VES, VES treated. B, PC-3 cells were plated on coverslip and treated with indicated concentration of VES for 24 h. Cells are stained by p38 antibody followed by FITC-conjugated anti-rabbit antibody.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    MKK6 activates NAG-1 promoter in a p38 kinase-dependent mechanism. A, PC-3 cells were cotransfected with NAG-1 promoter reporter plasmid (-966/70) and pcDNA3.1-lacZ or pcDNA3-MKK6b(E). As an internal control, the phRL-null vector was used to correct for transfection efficiency. Twenty-four hours after transfection, medium was changed and cells were incubated for another 24 h in the presence or absence of 20 μmol/L SB203580. Luciferase activity was measured 48 h after transfection and firefly luciferase activity was normalized to Renilla luciferase. B, PC-3 cells were cotransfected with indicated length of NAG-1 promoter reporter plasmid and pcDNA3.1-lacZ or pcDNA3-MKK6b(E). As an internal control, the phRL-null vector was used to correct for transfection efficiency. Luciferase activity was measured 48 h after transfection and firefly luciferase activity was normalized to Renilla luciferase.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    NAG-1 mRNA is stabilized by VES treatment in a p38 kinase-dependent mechanism. A, PC-3 cells were transfected with pGL3 promoter or pGL3 promoter plasmid with 3′-UTR of NAG-1. As an internal control, the phRL-null vector was used to correct for transfection efficiency. Twenty-four hours after transfection, cells were treated with or without VES for 48 h. Luciferase activity was measured and firefly luciferase activity was normalized to Renilla luciferase. B, PC-3 cells were cotransfected with pGL3 promoter or pGL3 promoter plasmid with 3′-UTR of NAG-1 and pcDNA3.1-lacZ or pcDNA3-MKK6b(E). As an internal control, the phRL-null vector was used to correct for transfection efficiency. Luciferase activity was measured 48 h after transfection and firefly luciferase activity was normalized to Renilla luciferase. C, PC-3 cells were treated with or without VES in the presence or absence of SB203580. Forty-eight hours after VES treatment, cells were treated with 5 μg/mL actinomycin D for the times indicated and NAG-1 mRNA levels adjusted to actin were measured by real-time reverse transcription-PCR analysis. The level of NAG-1 mRNA was expressed as the percentage of the NAG-1 mRNA at the 0 h of actinomycin D treatment in each group.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    NAG-1 siRNA-expressing PC-3 cells are resistant to VES-induced apoptosis. Empty vector or NAG-1 siRNA-expressing PC-3 cells were treated with 20 μmol/L VES for 48 h. Total lysates were subjected to Western blot analysis for PARP and NAG-1. For Western analysis, 39-kDa form of NAG-1 protein (proform) was shown. The membrane was stripped and reprobed for β-actin to confirm equal loading.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (4)
April 2008
Volume 7, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism
Minsub Shim and Thomas E. Eling
Mol Cancer Ther April 1 2008 (7) (4) 961-971; DOI: 10.1158/1535-7163.MCT-07-0470

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism
Minsub Shim and Thomas E. Eling
Mol Cancer Ther April 1 2008 (7) (4) 961-971; DOI: 10.1158/1535-7163.MCT-07-0470
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement